Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HMBD-001 |
Synonyms | |
Therapy Description |
HMBD-001 is a monoclonal antibody that binds ERBB3 (HER3) and prevents heterodimer formation, potentially inhibiting tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P197). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HMBD-001 | HMBD001|HMBD 001 | HER3 (ERBB3) Antibody 23 | HMBD-001 is a monoclonal antibody that binds ERBB3 (HER3) and prevents heterodimer formation, potentially inhibiting tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P197). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05919537 | Phase Ib/II | Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | Active, not recruiting | AUS | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |